Drug-eluting stents

Drug-eluting stents (DES) are a type of coronary stent used in percutaneous coronary intervention (PCI) that slowly release a drug to block cell proliferation. This prevents fibrosis that, together with clots, could otherwise block the stented artery, a process known as in-stent restenosis. The development of DES was a major advancement in the treatment of coronary artery disease (CAD), significantly reducing the risk of restenosis compared to bare-metal stents (BMS).

History

The first drug-eluting stent was approved for use in Europe in 2002 and in the United States in 2003. These stents were coated with sirolimus or paclitaxel, drugs that inhibit cell proliferation. Since then, several generations of DES have been developed, featuring different drugs, coatings, and stent designs to improve efficacy and safety.

Mechanism of Action

Drug-eluting stents are designed to perform two main functions: scaffolding the artery to keep it open and delivering medication directly to the artery's lining to prevent restenosis. The drugs used in DES are typically anti-proliferative agents that inhibit the growth of smooth muscle cells in the artery wall. By releasing the drug locally, at the site of stent placement, DES minimize systemic side effects associated with oral or intravenous administration of such medications.

Types of Drugs Used

The first-generation DES used sirolimus (also known as rapamycin) and paclitaxel. Newer generations have introduced other drugs such as zotarolimus, everolimus, and biolimus, which have similar mechanisms of action but different pharmacokinetic profiles that may offer advantages in certain patient populations.

Advantages and Disadvantages

The primary advantage of drug-eluting stents over bare-metal stents is their ability to significantly reduce the rate of in-stent restenosis, thereby decreasing the need for repeat revascularization procedures. However, DES require longer periods of dual antiplatelet therapy (DAPT) to prevent stent thrombosis, a rare but serious complication. This prolonged DAPT use can increase the risk of bleeding.

Clinical Trials

Numerous clinical trials have demonstrated the efficacy and safety of DES. Trials such as the RAVEL, SIRIUS, and TAXUS studies have shown significant reductions in the rates of restenosis and the need for repeat procedures compared to bare-metal stents. Ongoing research continues to compare different generations of DES and their long-term outcomes.

Future Directions

Research in the field of drug-eluting stents is focused on developing new drugs, coatings, and stent materials to further reduce the risk of restenosis and stent thrombosis. Bioresorbable stents, which are designed to dissolve after fulfilling their purpose, represent an emerging area of interest. Additionally, efforts are being made to reduce the duration of required dual antiplatelet therapy without compromising safety.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian